Inhibikase Therapeutics, Inc. Common Stock
IKTInhibikase Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing kinase inhibitors for the treatment of neurodegenerative and infectious diseases. The company's approach involves targeting aberrant kinase activity involved in disease progression, aiming to create therapies with improved safety and efficacy profiles. Founded with an emphasis on precision medicine, Inhibikase leverages its expertise in kinase biology to advance novel therapeutic candidates.
Company News
Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics en...
Inhibikase Therapeutics announced the grant of non-qualified stock options to purchase 685,718 shares to five newly-hired non-executive employees under its 2026 Inducement Equity Plan. The options have an exercise price of $1.68 per share with a ten-year term and a standard vesting schedule of 25% after one year followed by 36 monthly installments.
Inhibikase Therapeutics is conducting a public offering of common stock and pre-funded warrants, raising approximately $100 million to support its clinical-stage pharmaceutical development for pulmonary arterial hypertension.
A Polish credit bureau analysis reveals that including Buy Now Pay Later (BNPL) transaction data in credit histories could help nearly 40% of 'thin-file' bank customers improve their creditworthiness, with BNPL transactions showing high repayment rates and low default risks.
